Skip to main content

Featured Content

As children diagnosed with attention-deficit/hyperactivity disorder transition into adolescence and young adulthood, primary care providers are missing the mark in monitoring them for several important health risks, a study warns.
The National Institute on Alcohol Abuse and Alcoholism (NIAAA) is slated for a particularly steep cut in the Trump administration's 2021 budget proposal.
Alaap B. Shah of Epstein Becker Green discusses the ways in which artificial intelligence can improve care, as well as the hurdles it presents to providers, payers and regulators.
AXS-05, which significantly improved symptoms of depression in a recent phase 3 trial, combines dextromethorphan and which antidepressant?
Psychiatrist Sarah Vinson, MD, associate clinical professor of psychiatry and pediatrics at Morehouse School of Medicine, Atlanta, Georgia, will coach attendees on trauma diagnosis and treatment at the upcoming Elevate by Psych Congress conference.
Christoph U. Correll, MD, discusses the results of the ENLIGHTEN‑2 study, which compared weight gain and cardiometabolic side effects in patients taking olanzapine and patients taking olanzapine plus samidorphan.
A label update for the insomnia drug Belsomra (suvorexant) C-IV adds study findings on its use in treating insomnia in patients with mild-to-moderate Alzheimer’s disease, drugmaker Merck announced.

Meetings & Publications

Back to Top